• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Danaher Corporation

    6/8/26 9:48:27 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials
    Get the next $DHR alert in real time by email
    S-8 1 d129292ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 8, 2026

    Registration No. 333

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Danaher Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   59-1995548

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    2200 Pennsylvania Avenue, N.W., Suite 800W

    Washington, DC 20037-1701

    (Address of Principal Executive Offices) (Zip Code)

    Masimo Corporation 2017 Equity Incentive Plan, as Amended

    (Full title of the plans)

    James F. O’Reilly

    Senior Vice President, Deputy General Counsel and Secretary

    Danaher Corporation

    2200 Pennsylvania Avenue, N.W., Suite 800W

    Washington, DC 20037-1701

    (Name and address of agent for service)

    (202) 828-0850

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Daniel Wolf, P.C.

    Daniel M. Klein, P.C.

    Brian Junquera

    Kirkland & Ellis LLP

    601 Lexington Avenue

    New York, New York 10022

    (212) 446-4800

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting Registrant, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    On February 16, 2026, Danaher Corporation (“Danaher” or the “Registrant”), Masimo Corporation (“Masimo”) and Mobius Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Registrant (“Merger Sub”), entered into the Agreement and Plan of Merger, pursuant to which Merger Sub will merge with and into Masimo, with Masimo surviving the Merger as a wholly owned subsidiary of the Registrant (the “Merger”).

    In connection with the Merger, each restricted stock unit (an “RSU”) in respect of shares of Masimo common stock that are granted and outstanding as of immediately prior to the effective time of the Merger (the “Rollover RSUs”) under the Masimo Corporation 2017 Equity Incentive Plan (as amended, the “Masimo Plan”), will be assumed by the Registrant and converted into RSUs in respect of shares of the Registrant’s common stock, par value $0.01 per share (“Common Stock”) subject to substantially the same terms and conditions as were applicable to the Rollover RSUs with respect to a number of shares of Common Stock determined by multiplying the number of Rollover RSUs immediately prior to the effective time of the Merger by $180.00 in cash, without interest, divided by the volumed weighted average trading price per share of Common Stock for the 10-day trading period ending on and including the closing date, as reported by the New York Stock Exchange.

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by the Registrant to register the offer and sale of up to 752,000 shares of Common Stock that may be issued pursuant to the Masimo Plan, which shares of Common Stock represent the number of shares of Masimo common stock issuable upon vesting of the Rollover RSUs, adjusted pursuant to the terms of the Merger Agreement described above.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information.

    The documents containing the information specified in Part I of Form S-8 will be delivered to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the instructions of Part I of Form S-8, such documents are not being filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Certain Documents by Reference.

    The following documents, which have heretofore been filed by the Registrant with the Commission pursuant to the Securities Act and pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference herein and shall be deemed to be a part hereof:

     

    (a)

    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Commission on February 24, 2026;

     

    (b)

    The information specifically incorporated by reference into the Annual Report on Form 10-K for the fiscal year ended December  31, 2025 from the Registrant’s definitive proxy statement on Schedule 14A, filed with the Commission on March 25, 2026;

     

    (c)

    the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 27, 2026 filed with the Commission on April 21, 2026;


    (d)

    the Registrant’s Current Reports on Form 8-K filed with the Commission on February  10, 2026, February  17, 2026, April  17, 2026, April  29, 2026, May  7, 2026, and June 3, 2026; and

     

    (e)

    the description of the Registrant’s common stock contained in the Exhibit 4.12 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Commission on February 20, 2025, and any amendments or reports filed for the purpose of updating such description.

    In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicate that all securities offered hereby have been sold or which deregister all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information that the Registrant discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.

    Any statement, including financial statements, contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or therein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the General Corporation Law of the State of Delaware (“DGCL”) provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

    Section 102(b)(7) of the DGCL provides, generally, that the certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such provision may not eliminate or limit the liability of (i) a director or officer for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) a director under section 174 of the DGCL, (iv) a director or officer for any transaction from which the director derived an improper personal benefit or (v) an officer in any action by or in the right of the corporation. No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such provision became effective.


    Article Nine of Danaher’s Restated Certificate of Incorporation provides that Danaher will indemnify its directors and officers to the full extent authorized or permitted by law and that no director shall be personally liable for monetary damages to Danaher or its stockholders for any breach of fiduciary duty by such director as a director, except to the extent provided by applicable law (i) for any breach of the director’s duty of loyalty to Danaher or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the DGCL, or (iv) for any transaction from which such director derived an improper personal benefit. Article Eight of Danaher’s Amended and Restated By-Laws provides that Danaher will indemnify directors and officers of Danaher in non-derivative claims if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of Danaher, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. For non-derivative claims, termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, in itself, create a presumption that the person did not act in good faith and in a manner which such person believed to be in or not opposed to the best interests of Danaher, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person’s conduct was unlawful. For derivative claims, Article Eight of Danaher’s By-Laws provides that Danaher will indemnify directors and officers of Danaher if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of Danaher; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to Danaher unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    In addition to the above, Danaher has entered into indemnification agreements with each of its directors and executive officers. The indemnification agreements provide for substantially similar indemnification rights and provide that Danaher will agree to pay expenses in advance of the final disposition of any proceeding for which indemnification is claimed. Danaher also provides indemnity insurance pursuant to which officers and directors are indemnified or insured against liability or loss under certain circumstances, which may include liability or related loss under the Securities Act and the Exchange Act.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    See Exhibit Index.

    Item 9. Undertakings.

     

    (a)

    The undersigned Registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to the Registration Statement:

     

      (i)

    To include any prospectus required by section 10(a)(3) of the Securities Act;

     

      (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed


      that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

      (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    EXHIBIT INDEX

     

    Exhibit

    Number

      

    Description

     4.1    Restated Certificate of Incorporation of Danaher Corporation (filed with the Commission on June  29, 2012, as Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q and incorporated herein by reference)
     4.2    Amended and Restated By-laws of Danaher Corporation (filed with the Commission on September 10, 2025, as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K and incorporated herein by reference)
     5.1*    Opinion of Kirkland & Ellis LLP
    10.1    Masimo Corporation 2017 Equity Incentive Plan, as amended (filed with the Commission on April  12, 2017, as Appendix B to Masimo’s Definitive Proxy Statement on Schedule 14A and incorporated herein by reference)
    23.1*    Consent of Ernst & Young LLP, independent registered public accounting firm of Danaher Corporation
    23.2*    Consent of Kirkland & Ellis LLP (included in Exhibit 5.1)
    24.1*    Power of Attorney of Danaher Corporation
    107*    Filing Fee Table
     
    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933 the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the District of Columbia, on June 8, 2026.

     

    DANAHER CORPORATION

     

    By:  

    /s/ Matthew Gugino

      Name:   Matthew Gugino
      Title:   Executive Vice President and Chief Financial Officer

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons on June 8, 2026 in the capacities indicated.

     

    Signature

      

    Title

      

    Date

    *

    Rainer M. Blair

      

    President and Chief Executive Officer and Director

    (Principal Executive Officer)

       June 8, 2026

    *

    Matthew Gugino

      

    Executive Vice President and Chief Financial Officer

    (Principal Financial Officer)

       June 8, 2026

    *

    Christopher Bouda

      

    Vice President and Chief Accounting Officer

    (Principal Accounting Officer)

       June 8, 2026

    *

    Steven M. Rales

       Chairman of the Board and Director    June 8, 2026

    *

    Mitchell P. Rales

       Chairman of the Executive Committee and Director    June 8, 2026

    *

    Feroz Dewan

       Director    June 8, 2026

    *

    Linda Filler

       Director    June 8, 2026

    *

    Charles W. Lamanna

       Director    June 8, 2026

    *

    Teri List

       Director    June 8, 2026

    *

    A. Shane Sanders

       Director    June 8, 2026

    *

    Alan G. Spoon

       Director    June 8, 2026

    *

    Raymond C. Stevens, Ph.D.

       Director    June 8, 2026

    *

    Elias A. Zerhouni, M.D.

       Director    June 8, 2026

     

    *

    The undersigned, by signing his name hereto, does hereby sign this report on behalf of each of the above-indicated directors and officers of the registrant pursuant to powers of attorney executed by such directors and officers.


    By:  

    /s/ James F. O’Reilly

      James F. O’Reilly,
      Attorney-in-fact
    Get the next $DHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DHR

    DatePrice TargetRatingAnalyst
    6/11/2026$200.00Neutral
    Piper Sandler
    6/3/2026$210.00Buy
    DZ Bank
    6/2/2026Peer Perform
    Wolfe Research
    5/26/2026$230.00Buy
    Citigroup
    5/15/2026$200.00Outperform
    RBC Capital Mkts
    12/9/2025$265.00Buy
    Goldman
    12/2/2025$270.00Overweight
    Morgan Stanley
    10/8/2025$220.00Buy → Neutral
    Rothschild & Co Redburn
    More analyst ratings

    $DHR
    SEC Filings

    View All

    SEC Form 11-K filed by Danaher Corporation

    11-K - DANAHER CORP /DE/ (0000313616) (Filer)

    6/16/26 5:09:15 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form S-8 filed by Danaher Corporation

    S-8 - DANAHER CORP /DE/ (0000313616) (Filer)

    6/8/26 9:48:27 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Corporation filed SEC Form 8-K: Other Events

    8-K - DANAHER CORP /DE/ (0000313616) (Filer)

    6/3/26 4:30:18 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Danaher with a new price target

    Piper Sandler initiated coverage of Danaher with a rating of Neutral and set a new price target of $200.00

    6/11/26 8:10:54 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    DZ Bank initiated coverage on Danaher with a new price target

    DZ Bank initiated coverage of Danaher with a rating of Buy and set a new price target of $210.00

    6/3/26 8:10:49 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Wolfe Research resumed coverage on Danaher

    Wolfe Research resumed coverage of Danaher with a rating of Peer Perform

    6/2/26 8:32:53 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Human Resources Couchara Georgeann covered exercise/tax liability with 281 shares, decreasing direct ownership by 3% to 8,291 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    5/19/26 5:10:04 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Director Filler Linda was granted 680 shares, increasing direct ownership by 3% to 24,712 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    5/19/26 5:10:11 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Director Stevens Raymond C was granted 680 shares, increasing direct ownership by 5% to 13,728 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    5/19/26 5:09:58 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Leadership Updates

    Live Leadership Updates

    View All

    Sirius XM Holdings Set to Join S&P MidCap 400

    NEW YORK, June 8, 2026 /PRNewswire/ -- Sirius XM Holdings Inc. (NASD: SIRI) will replace Masimo Corp. (NASD: MASI) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, June 11. S&P 500 & 100 constituent Danaher Corp. (NYSE:DHR) is acquiring Masimo in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Date Index Name Action Company Name Ticker GICS Sector  June 11, 2026  S&P MidCap 400 Addition Sirius XM HoldingsSIRI Communication Services  June 11, 2026  S&P MidCap 400 Deletion MasimoMASI Health Care ABOUT S&P DOW JONES INDICESS&P Dow Jon

    6/8/26 6:09:00 PM ET
    $DHR
    $MASI
    $SIRI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    AstroNova Appoints Jorik E. Ittmann as President and Chief Executive Officer

    Leverages Mr. Ittmann's extensive print industry and international business experience Padraig Finn, with over 16 years in the print industry, promoted to Senior Vice President, Product Identification Tom Carll, Senior Vice President, Aerospace, Thomas DeByle, CFO, and Michael Natalizia, Chief Technology Officer, round out the Executive Leadership Team Darius G. Nevin appointed Executive Chairman AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions that enable data visualization, today announced that the Board of Directors has promoted Jorik E. Ittmann to President and CEO and appointed him to the Board of Directors, both to be effective

    8/4/25 9:00:00 AM ET
    $ALOT
    $DHR
    $VLTO
    Computer peripheral equipment
    Technology
    Industrial Machinery/Components
    Industrials

    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Danaher Schedules Second Quarter 2026 Earnings Conference Call

    WASHINGTON, June 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.You can

    6/22/26 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk Sooner

    Powered by smartSET™, the Pattern Recognition Capability Analyzes Continuous Patient Data to Provide Clinicians With Earlier Insight Into Opioid-Related Respiratory Risk Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Enabled by Masimo’s next-generation smartSET™ pulse oximetry sensor platform, the new feature uses advanced pattern recognition that analyzes continuous physiologic data to help clinicians identify early signs of respirator

    6/22/26 8:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Completes Acquisition of Masimo Corporation

    WASHINGTON, June 10, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings. Masimo's trusted brand, advanced sensor technology and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio. As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has ceased trading on the Nasdaq Stock Market. Masimo will continue to operate unde

    6/10/26 8:55:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Financials

    Live finance-specific insights

    View All

    Danaher Schedules Second Quarter 2026 Earnings Conference Call

    WASHINGTON, June 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.You can

    6/22/26 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Completes Acquisition of Masimo Corporation

    WASHINGTON, June 10, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings. Masimo's trusted brand, advanced sensor technology and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio. As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has ceased trading on the Nasdaq Stock Market. Masimo will continue to operate unde

    6/10/26 8:55:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Announces Quarterly Dividend

    WASHINGTON, May 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 31, 2026 to holders of record on June 26, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.Pow

    5/5/26 4:30:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

    SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    2/9/23 11:16:32 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

    SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    2/9/22 3:43:35 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D/A filed by Danaher Corporation (Amendment)

    SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)

    11/2/21 9:29:29 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials